FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898886293> ?p ?o ?g. }

• W2898886293 endingPage "100113" @default.
• W2898886293 startingPage "100113" @default.
• W2898886293 abstract "The phase II JO28638 study evaluated first-line onartuzumab plus erlotinib in patients with MET-positive advanced, metastatic, or post-operative recurrent non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The study was stopped following termination of the global METLung study (OAM4971g), which showed lack of efficacy in the onartuzumab/erlotinib arm. We present immature efficacy and safety data from JO28638. Chemotherapy-naïve patients aged ≥ 20 years were enrolled. Patients received onartuzumab (15 mg/kg every 3 weeks) plus erlotinib (150 mg once daily) until progression or unacceptable toxicity. The co-primary endpoints were investigator (INV)-assessed progression-free survival (PFS) and safety. Secondary endpoints: overall response rate (ORR), disease control rate (DCR), overall survival (OS), duration of response (DOR), and pharmacokinetics. Exploratory biomarker analyses were also conducted. 61 patients received treatment. Median age was 67 years and most patients had stage IV NSCLC (71%), MET-IHC score 2 (87%), and exon 19 deletion EGFR mutation (53%). Median PFS (INV) was 8.5 months (95% confidence interval [CI] 6.8–12.4); median OS was 15.6 months (95% CI 15.6–not evaluable); ORR was 68.9% (95% CI 55.7–80.1); median DOR was not reached; DCR was 88.5% (95% CI 77.8–95.3). Pharmacokinetics were similar to previous studies. All patients experienced an adverse event (AE); 26 patients discontinued treatment due to AEs; no grade 5 AEs were reported. No significant correlation was found between biomarkers and efficacy outcomes. The results presented are inconclusive due to the early termination of the study." @default.
• W2898886293 created "2018-11-09" @default.
• W2898886293 creator A5020327537 @default.
• W2898886293 creator A5021695259 @default.
• W2898886293 creator A5024261346 @default.
• W2898886293 creator A5024933822 @default.
• W2898886293 creator A5031839858 @default.
• W2898886293 creator A5034276209 @default.
• W2898886293 creator A5040817459 @default.
• W2898886293 creator A5047714811 @default.
• W2898886293 creator A5067259938 @default.
• W2898886293 creator A5074862416 @default.
• W2898886293 creator A5078287634 @default.
• W2898886293 date "2019-01-01" @default.
• W2898886293 modified "2023-10-03" @default.
• W2898886293 title "First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer" @default.
• W2898886293 cites W1788867760 @default.
• W2898886293 cites W1967394241 @default.
• W2898886293 cites W1987709860 @default.
• W2898886293 cites W1994912526 @default.
• W2898886293 cites W2014230197 @default.
• W2898886293 cites W2055597038 @default.
• W2898886293 cites W2069421644 @default.
• W2898886293 cites W2072120492 @default.
• W2898886293 cites W2080348781 @default.
• W2898886293 cites W2101581271 @default.
• W2898886293 cites W2111662961 @default.
• W2898886293 cites W2119351872 @default.
• W2898886293 cites W2124717208 @default.
• W2898886293 cites W2136390065 @default.
• W2898886293 cites W2136601558 @default.
• W2898886293 cites W2138297714 @default.
• W2898886293 cites W2140334822 @default.
• W2898886293 cites W2146137201 @default.
• W2898886293 cites W2164042520 @default.
• W2898886293 cites W2562169753 @default.
• W2898886293 cites W2765258454 @default.
• W2898886293 doi "https://doi.org/10.1016/j.ctarc.2018.10.004" @default.
• W2898886293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30472556" @default.
• W2898886293 hasPublicationYear "2019" @default.
• W2898886293 type Work @default.
• W2898886293 sameAs 2898886293 @default.
• W2898886293 citedByCount "7" @default.
• W2898886293 countsByYear W28988862932019 @default.
• W2898886293 countsByYear W28988862932020 @default.
• W2898886293 countsByYear W28988862932021 @default.
• W2898886293 countsByYear W28988862932023 @default.
• W2898886293 crossrefType "journal-article" @default.
• W2898886293 hasAuthorship W2898886293A5020327537 @default.
• W2898886293 hasAuthorship W2898886293A5021695259 @default.
• W2898886293 hasAuthorship W2898886293A5024261346 @default.
• W2898886293 hasAuthorship W2898886293A5024933822 @default.
• W2898886293 hasAuthorship W2898886293A5031839858 @default.
• W2898886293 hasAuthorship W2898886293A5034276209 @default.
• W2898886293 hasAuthorship W2898886293A5040817459 @default.
• W2898886293 hasAuthorship W2898886293A5047714811 @default.
• W2898886293 hasAuthorship W2898886293A5067259938 @default.
• W2898886293 hasAuthorship W2898886293A5074862416 @default.
• W2898886293 hasAuthorship W2898886293A5078287634 @default.
• W2898886293 hasBestOaLocation W28988862931 @default.
• W2898886293 hasConcept C121608353 @default.
• W2898886293 hasConcept C126322002 @default.
• W2898886293 hasConcept C143998085 @default.
• W2898886293 hasConcept C197934379 @default.
• W2898886293 hasConcept C203092338 @default.
• W2898886293 hasConcept C2776256026 @default.
• W2898886293 hasConcept C2778087573 @default.
• W2898886293 hasConcept C2779438470 @default.
• W2898886293 hasConcept C2909325608 @default.
• W2898886293 hasConcept C535046627 @default.
• W2898886293 hasConcept C71924100 @default.
• W2898886293 hasConcept C90924648 @default.
• W2898886293 hasConceptScore W2898886293C121608353 @default.
• W2898886293 hasConceptScore W2898886293C126322002 @default.
• W2898886293 hasConceptScore W2898886293C143998085 @default.
• W2898886293 hasConceptScore W2898886293C197934379 @default.
• W2898886293 hasConceptScore W2898886293C203092338 @default.
• W2898886293 hasConceptScore W2898886293C2776256026 @default.
• W2898886293 hasConceptScore W2898886293C2778087573 @default.
• W2898886293 hasConceptScore W2898886293C2779438470 @default.
• W2898886293 hasConceptScore W2898886293C2909325608 @default.
• W2898886293 hasConceptScore W2898886293C535046627 @default.
• W2898886293 hasConceptScore W2898886293C71924100 @default.
• W2898886293 hasConceptScore W2898886293C90924648 @default.
• W2898886293 hasFunder F4320333003 @default.
• W2898886293 hasLocation W28988862931 @default.
• W2898886293 hasLocation W28988862932 @default.
• W2898886293 hasOpenAccess W2898886293 @default.
• W2898886293 hasPrimaryLocation W28988862931 @default.
• W2898886293 hasRelatedWork W1507819140 @default.
• W2898886293 hasRelatedWork W1667731616 @default.
• W2898886293 hasRelatedWork W1976268611 @default.
• W2898886293 hasRelatedWork W2005973176 @default.
• W2898886293 hasRelatedWork W2025083754 @default.
• W2898886293 hasRelatedWork W2037032877 @default.
• W2898886293 hasRelatedWork W2186047679 @default.
• W2898886293 hasRelatedWork W2218718059 @default.
• W2898886293 hasRelatedWork W2467851859 @default.

• next